KCM
HRMY icon

Kendall Capital Management’s Harmony Biosciences HRMY Stock Holding History

Kendall Capital Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$262K Sell
7,190
-505
-7% -$15.9K 0.04% 208
2026
Q1 		$216K Buy
+7,695
New +$252K 0.04% 220

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kendall Capital Management's HRMY Position: Q2 2026 in Review

Kendall Capital Management reduced its Harmony Biosciences (HRMY) stake by 6.6% in Q2 2026, selling an estimated $15.9K and leaving 7,190 shares worth $262K. The position accounts for 0.04% of the portfolio, ranked #208.

Kendall Capital Management first reported a position in HRMY in Q1 2026 and has held it in 2 quarters since. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Kendall Capital Management held 7,190 shares of Harmony Biosciences worth $262K as of Q2 2026.
  • Kendall Capital Management sold 505 Harmony Biosciences shares in Q2 2026, an estimated $15.9K.
  • Harmony Biosciences made up 0.04% of Kendall Capital Management's portfolio in Q2 2026, its #208 holding.
  • Kendall Capital Management first reported a position in Harmony Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Kendall Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.